Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Cancer Cell

Volumn 17, Issue 1, 2010, Pages 77-88

  Turke, Alexa B ^a,b   Zejnullahu, Kreshnik ^c,d   Wu, Yi Long ^e   Song, Youngchul ^a   Dias Santagata, Dora ^a   Lifshits, Eugene ^a   Toschi, Luca ^c,d   Rogers, Andrew ^c,d   Mok, Tony ^f   Sequist, Lecia ^a   Lindeman, Neal I ^g   Murphy, Carly ^g   Akhavanfard, Sara ^a   Yeap, Beow Y ^a,b   Xiao, Yun ^d,g   Capelletti, Marzia ^c,d   Iafrate, A John ^a   Lee, Charles ^g   Christensen, James G ^h   Engelman, Jeffrey A ^a,b   Jänne, Pasi A ^b,c,d,g   more..

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Lowe Center for Thoracic Oncology   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

CELLCYCLE

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; LAPATINIB; LIGAND; SCATTER FACTOR RECEPTOR;

ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME INHIBITION; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE ACTIVATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR CLONING; MUTANT; PRIORITY JOURNAL; SCATTER FACTOR RECEPTOR GENE; SIGNAL TRANSDUCTION;

EID: 73649102105     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2009.11.022     Document Type: Article

References (35)

1. Asahina H., Yamazaki K., Kinoshita I., Sukoh N., Harada M., Yokouchi H., Ishida T., Ogura S., Kojima T., Okamoto Y., et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br. J. Cancer 95 (2006) 998-1004
2. Balak M.N., Gong Y., Riely G.J., Somwar R., Li A.R., Zakowski M.F., Chiang A., Yang G., Ouerfelli O., Kris M.G., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12 (2006) 6494-6501
3. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., Chitale D., Motoi N., Szoke J., Broderick S., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA 104 (2007) 20932-20937
4. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347 (2002) 472-480
5. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., and Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344 (2001) 1038-1042
6. Engelman J.A., and Janne P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 14 (2008) 2895-2899
7. Engelman J.A., Janne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., Cichowski K., Johnson B.E., and Cantley L.C. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA 102 (2005) 3788-3793
8. Engelman J.A., Mukohara T., Zejnullahu K., Lifshits E., Borras A.M., Gale C.M., Naumov G.N., Yeap B.Y., Jarrell E., Sun J., et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 116 (2006) 2695-2706
9. Engelman J.A., Zejnullahu K., Gale C.M., Lifshits E., Gonzales A.J., Shimamura T., Zhao F., Vincent P.W., Naumov G.N., Bradner J.E., et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 67 (2007) 11924-11932
10. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007) 1039-1043
11. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., and Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
12. Guix M., Faber A.C., Wang S.E., Olivares M.G., Song Y., Qu S., Rinehart C., Seidel B., Yee D., Arteaga C.L., and Engelman J.A. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 118 (2008) 2609-2619
13. Hellman A., Zlotorynski E., Scherer S.W., Cheung J., Vincent J.B., Smith D.I., Trakhtenbrot L., and Kerem B. A role for common fragile site induction in amplification of human oncogenes. Cancer Cell 1 (2002) 89-97
14. Hofmann W.K., Komor M., Wassmann B., Jones L.C., Gschaidmeier H., Hoelzer D., Koeffler H.P., and Ottmann O.G. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 102 (2003) 659-661
15. Inoue A., Suzuki T., Fukuhara T., Maemondo M., Kimura Y., Morikawa N., Watanabe H., Saijo Y., and Nukiwa T. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol. 24 (2006) 3340-3346
16. Janne P.A., Borras A.M., Kuang Y., Rogers A.M., Joshi V.A., Liyanage H., Lindeman N., Lee J.C., Halmos B., Maher E.A., et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin. Cancer Res. 12 (2006) 751-758
17. Janne, P.A., Schellens, J.H., Engelman, J.A., Eckhardt, S.G., Millham, R., Denis, L.J., Britten, C.D., Wong, S.G., Boss, D.S., and Camidge, D.R. (2008). Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC. J. Clin. Oncol. ASCO Annual Meeting Proceedings 26, abstract 8027.
18. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., and Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352 (2005) 786-792
19. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., Tada H., Kuwano H., and Mitsudomi T. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res. 12 (2006) 5764-5769
20. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., Inserra E., Diederichs S., Iafrate A.J., Bell D.W., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359 (2008) 366-377
21. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo J., Sunpaweravong P., Han B., Margono B., Ichinose Y., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361 (2009) 947-957
22. Ogino A., Kitao H., Hirano S., Uchida A., Ishiai M., Kozuki T., Takigawa N., Takata M., Kiura K., and Tanimoto M. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res. 67 (2007) 7807-7814
23. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., and Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2 (2005) e73
24. Riely G.J. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J. Thorac. Oncol. 3 (2008) S146-S149
25. Roche-Lestienne C., Lai J.L., Darre S., Facon T., and Preudhomme C. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. N. Engl. J. Med. 348 (2003) 2265-2266
26. Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N., Lai J.L., Philippe N., Facon T., Fenaux P., and Preudhomme C. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100 (2002) 1014-1018
27. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., Majem M., Lopez-Vivanco G., Isla D., Provencio M., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361 (2009) 958-967
28. Schellens, J. H., Britten, C. D., Camidge, D. R., Boss, D., Wong, S., Diab, S., Guo, F., Maguire, R. P., Letrent, S. P., and Eckhardt, S. G. (2007). First-in-human study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-00299804, a small molecule irreversible pan-HER inhibitor in patients with advanced cancer. J. Clin. Oncol. ASCO Annual Meeting Proceedings 25, abstract 3599.
29. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Janne P.A., Joshi V.A., McCollum D., Evans T.L., Muzikansky A., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 26 (2008) 2442-2449
30. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., and Sawyers C.L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
31. Tamura K., Okamoto I., Kashii T., Negoro S., Hirashima T., Kudoh S., Ichinose Y., Ebi N., Shibata K., Nishimura T., et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br. J. Cancer 98 (2008) 907-914
32. Yano S., Wang W., Li Q., Matsumoto K., Sakurama H., Nakamura T., Ogino H., Kakiuchi S., Hanibuchi M., Nishioka Y., et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68 (2008) 9479-9487
33. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., Meyerson M., and Eck M.J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. USA 105 (2008) 2070-2075
34. Zhao L., and Vogt P.K. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. USA 105 (2008) 2652-2657
35. Zou H.Y., Li Q., Lee J.H., Arango M.E., McDonnell S.R., Yamazaki S., Koudriakova T.B., Alton G., Cui J.J., Kung P.P., et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67 (2007) 4408-4417